NASDAQ OMX

Medable Launches Synapse, a Fully Integrated Clinical Care App Platform Using CareKit

9.6.2017 19:10 | NASDAQ OMX

Dela

Medable's next generation disease management solution seeks to significantly improve health outcomes through provider and patient directed apps that track and trend patient health in real-time

PALO ALTO, Calif., June 09, 2017 (GLOBE NEWSWIRE) -- Medable Inc.--the leading app and analytics platform for healthcare--today announced the release of Synapse, the first cloud solution to enable Apple's new CareKit Bridge APIs for real time health management on iOS.

Synapse enables healthcare organizations to seamlessly launch CareKit apps for not only their patients but now for their care teams. Synapse allows providers and patients to track and trend health in real-time, addressing the massive cost issues from poor communication, including preventable readmissions. In addition to app creation, Synapse provides user and data management, HIPAA compliance, EMR interoperability, and outcomes analytics. Early use cases include clinical trials, chronic disease management, and post-op care. For example, a post-operative care app for hip replacement that enables a patient to track pain medication usage, monitor for surgical site infection, track mobility metrics, and communicate with the care team, all from the comfort of the patient's own home.

"Too often the care delivered within the walls of hospitals is undermined by a lack of clear guidance for patients after visits," said Dr. Michelle Longmire, Medable CEO. "Medable's platform, built using CareKit, allows healthcare organizations to open the door for clear and continuous care, anytime, anywhere."

Longmire said Medable is working with leading healthcare institutions to bring its advanced technology to the forefront of patient management.

"CareKit is a powerful tool for improving health outcomes and is a practical solution for harnessing innovation to address huge, long standing problems in healthcare," said Longmire. "As an industry, healthcare is realizing the power of mobile as a conduit for better healthcare."

For more information about Synapse: www.medable.com/synapse

ABOUT MEDABLE

Privately-held Palo Alto, California-based Medable provides a comprehensive, secure HIPAA-compliant cloud-based platform purpose-built for healthcare. Medable's Synapse is a clinical care app solution for providers and patients. Medable's award-winning Cortex is the fastest way for developers to create scalable, EHR interoperable, HIPAA compliant applications. Medable's Axon is a "no coding required" solution enabling researchers to deliver smartphone clinical studies on a secure, HIPAA compliant technology stack. Medable's Cerebrum is the first cloud-based machine learning solution created specifically for healthcare apps. For more information visit: www.medable.com

Follow Medable on Twitter: @medableinc

Gary Poole, PR Director
gary@medable.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medable via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Forterra Announces Second Quarter 2017 Earnings Schedule27.7.2017 22:30Pressmeddelande

IRVING, Texas, July 27, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release second quarter 2017 financial results before the market open on Thursday, August 10, 2017.  A conference call to review financial results will also be held on Thursday, August 10, 2017 at 8:30 a.m. Eastern time (7:30 a.m. Central).  Hosting the call will be Jeff Bradley, Chief Executive Officer, and Matt Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q2 2017 Forterra, Inc. Earnings Call Date: Thursday, August 10, 2017 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) Webcast: http://edge.media-server.com/m/p/uxphuyzt Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Parti

TGS Q2 2017 webcast and teleconference27.7.2017 18:14Pressmeddelande

ASKER, Norway, July 27, 2017 (GLOBE NEWSWIRE) -- TGS will release its Q2 2017 results at approximately 07:00 CEST on 3 August 2017. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at the Hotel Continental, Stortingsgata 24/26 in Oslo, Norway. The presentation is open to the public and can be followed live on the internet at www.tgs.com. The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. CEO Kristian Johansen and CFO Sven Børre Larsen will host a conference call on 3 August 2017 at 15:00 CEST (09:00 EDT). Attendees may want to call 5-10 minutes before to ensure registration and access. Norwegian attendees are invited to call + 800 51084 or + 47 2100 2610 International attendees are invited to call 0800 358 6377 or + 44 (0)330 336 9105 US attendees are invited to call +1 866-

Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36Pressmeddelande

VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850  VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching

Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30Pressmeddelande

Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.  The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270.  A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company's website beginning approximately two hours after

Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22Pressmeddelande

Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus

TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00Pressmeddelande

-   Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia -   TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum